10-K: Panacea Life Sciences Holdings Reports Increased Revenue in 2023, Focuses on Nutraceuticals and Expansion

Panacea Life Sciences Holdings saw a 47% increase in revenue in 2023, driven by a focus on nutraceutical contract manufacturing and the acquisition of N7 Enterprises.

Summary

• Panacea Life Sciences Holdings, a plant-based natural health company, reported a 47% increase in revenue for the year ended December 31, 2023, reaching $2,384,956, compared to $1,626,978 in 2022.
• The revenue growth was primarily attributed to increased focus on contract manufacturing for nutraceutical companies and the acquisition of N7 Enterprises, now Panacea Distro.
• The company's cost of sales increased by 3% to $1,262,979 in 2023, while operating expenses rose by 10% to $6,668,131.
• Operating expenses increased due to higher production-related costs and general and administrative expenses, including a $500,000 bad debt write-off from a receivable from XXII.
• The company experienced a net loss of $8,015,301 in 2023, compared to a net loss of $9,142,584 in 2022.
• Panacea Distro, acquired in September 2023, contributed $595,549 in revenue for the year.
• The company is planning to launch Pana Kava Java (PKJ) as a franchisor in Q3-Q4 2024, based on the success of its existing retail locations.
• Panacea is vertically integrated, controlling the value chain from hemp cultivation to finished products, and focuses on pharmaceutical formulation methods and GMP standards.
• The company is also involved in research at Colorado State University, studying the effects of cannabis extracts on human and animal health.

Sentiment

Score: 4

Explanation: The document shows positive revenue growth and strategic expansion, but significant losses, reliance on debt, and material weaknesses in internal controls temper the overall sentiment. The company's future is uncertain without additional capital.

Positives

• The company achieved a significant 47% increase in revenue year-over-year.
• The acquisition of N7 Enterprises (Panacea Distro) has added a new revenue stream and retail presence.
• The company is expanding into the franchise market with the launch of Pana Kava Java.
• Panacea's vertical integration and focus on quality control provide a competitive advantage.
• The company is actively engaged in research and development to expand its product offerings.
• The net loss decreased from $9,142,584 in 2022 to $8,015,301 in 2023.

Negatives

• The company experienced a net loss of $8,015,301 in 2023.
• Operating expenses increased by 10% due to higher production and administrative costs.
• A $500,000 bad debt write-off from a receivable from XXII impacted general and administrative expenses.
• The company has a history of losses and negative cash flows, raising concerns about its ability to continue as a going concern.
• The company is dependent on loans from its CEO and principal stockholder, Leslie Buttorff.
• The company's stock is considered a penny stock, which may limit its liquidity.

Risks

• The company's ability to continue as a going concern is in doubt unless it obtains adequate new debt or equity financing and achieves sufficient sales levels.
• The company is highly dependent on its Chief Executive Officer, Leslie Buttorff, and her loans to the company.
• The company faces substantial regulation and governmental scrutiny in the hemp industry.
• The company's stock price may be volatile and is subject to the penny stock rules.
• The company may face product liability claims based on its production and sale of products containing chemical compounds.
• The company's CEO owns a majority of the outstanding common stock, limiting other stockholders' influence.
• The company has material weaknesses in internal control over financial reporting, which could lead to errors and restatements.

Future Outlook

The company plans to expand its product offerings, grow its franchise business, and continue research and development in the cannabinoid space. The company is also seeking additional capital to fund operations and growth.

Management Comments

• Management believes that the company's competitive advantages are derived from being vertically integrated.
• Management believes that the skills, experience and industry knowledge of our key employees significantly benefit our operations and performance.
• Management believes it has sufficient human capital to operate its business successfully.

Industry Context

The company operates in the rapidly growing natural health and wellness market, which is valued at $134 billion. The company is also involved in the hemp and cannabinoid industry, which is subject to evolving regulations and market dynamics. The company is pivoting to nutraceuticals due to regulatory uncertainty in the CBD industry.

Comparison to Industry Standards

• The company's revenue growth of 47% is significant compared to many companies in the early stages of the hemp and nutraceutical industries.
• The company's vertical integration strategy is similar to some larger players in the cannabis and nutraceutical space, such as Curaleaf and Nutriband, which aim to control their supply chain.
• The company's focus on GMP standards and pharmaceutical formulation methods aligns with best practices in the pharmaceutical and nutraceutical industries, similar to companies like Catalent and Lonza.
• The company's research collaboration with Colorado State University is a strategic move to gain a competitive edge, similar to how companies like GW Pharmaceuticals have leveraged research to develop cannabinoid-based drugs.
• The company's move into franchising with Pana Kava Java is a unique approach in the hemp and nutraceutical space, which is more common in the food and beverage industry, similar to companies like Starbucks and Dunkin'.

Related Party Transactions

• The company leases its laboratory space from J&N Real Estate Company, LLC, which is owned by its CEO.
• The company has borrowed substantial sums from Leslie Buttorff, its Chief Executive Officer, to meet its working capital obligations.
• The company has a line of credit with Ms. Buttorff through which it may borrow up to $8 million at a 10% annual interest rate.
• The company has a related party liability (Fixed Asset Loan) in the amount of $3,059,474 relating to building leasehold improvements and SAP software and support fees which were paid by an affiliate company of the CEO.
• The company recorded an additional related party liability in the amount of $513,390 in respect of certain building improvements, due to J&N Real Estate Company.

Stakeholder Impact

• Shareholders face the risk of dilution from potential capital raises.
• Employees may be impacted by the company's financial instability.
• Customers may benefit from the company's expanded product offerings and retail presence.
• Suppliers may be affected by the company's financial performance and ability to pay.
• Creditors face the risk of non-payment due to the company's financial challenges.

Next Steps

• The company plans to launch Pana Kava Java (PKJ) as a franchisor in Q3-Q4 2024.
• The company will continue to focus on contract manufacturing for nutraceutical companies.
• The company will continue to develop and research new products.
• The company will seek additional capital to fund operations and growth.

Key Dates

Keywords

hemp, cannabinoid, nutraceutical, contract manufacturing, franchise, vertical integration, research, Panacea Life Sciences, Pana Kava Java, Panacea Distro, kratom, mushrooms